Safety about treatment-emergent adverse events (TEAE)
We compared HIF-PHIs with ESAs based on major TEAE risks, including AEs and SAEs, as the pooled results presented in Figures 2 and 3, and relative risks for specific adverse events in DD CKD patients are shown in Figures 4 and 5.